These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Clinicopathological Distinction of Low-AFP-Secreting vs. High-AFP-Secreting Hepatocellular Carcinomas. Gurakar A; Ma M; Garonzik-Wang J; Kim A; Anders RA; Oshima K; Georgiades C; Gurakar M; Ottmann S; Cameron AM; Philosophe B; Saberi B Ann Hepatol; 2018; 17(6):1052-1066. PubMed ID: 31208632 [TBL] [Abstract][Full Text] [Related]
24. Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease. Mahmud N; Shaked A; Olthoff KM; Goldberg DS Liver Transpl; 2019 Mar; 25(3):388-398. PubMed ID: 30362249 [TBL] [Abstract][Full Text] [Related]
25. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation. Jiang T; Zhang XS; Pan F; Lyu SC; Wang J; Huang MX; He Q; Lang R Medicine (Baltimore); 2021 Jul; 100(26):e26487. PubMed ID: 34190174 [TBL] [Abstract][Full Text] [Related]
26. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778 [TBL] [Abstract][Full Text] [Related]
27. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060 [TBL] [Abstract][Full Text] [Related]
29. Is inconsistency of alpha-fetoprotein level a good prognosticator for hepatocellular carcinoma recurrence? Hsieh CB; Chen TW; Chu CM; Chu HC; Yu CP; Chung KP World J Gastroenterol; 2010 Jun; 16(24):3049-55. PubMed ID: 20572309 [TBL] [Abstract][Full Text] [Related]
30. α-fetoprotein, vascular endothelial growth factor receptor-1 and early recurrence of hepatoma. Kamiyama T; Takahashi M; Nakanishi K; Yokoo H; Kamachi H; Kobayashi N; Ozaki M; Todo S World J Gastroenterol; 2012 Jan; 18(4):340-8. PubMed ID: 22294840 [TBL] [Abstract][Full Text] [Related]
31. Peri-Transplant Change in AFP Level: a Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation. Yoo T; Lee KW; Yi NJ; Choi YR; Kim H; Suh SW; Jeong JH; Lee JM; Suh KS J Korean Med Sci; 2016 Jul; 31(7):1049-54. PubMed ID: 27366001 [TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of Pre-transplantation Serum Alpha-Fetoprotein Levels in Hepatocellular Carcinoma Recurrence. Montalvá EM; Cantos M; Boscà A; Rubín A; Vinaixa C; Granero P; Maupoey J; López-Andújar R Transplant Proc; 2016 Nov; 48(9):2966-2968. PubMed ID: 27932120 [TBL] [Abstract][Full Text] [Related]
33. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. Halazun KJ; Rosenblatt RE; Mehta N; Lai Q; Hajifathalian K; Gorgen A; Brar G; Sasaki K; Doyle MBM; Tabrizian P; Agopian VG; Najjar M; Ivanics T; Samstein B; Brown RS; Emond JC; Yao F; Lerut J; Rossi M; Mennini G; Iesari S; Finkenstedt A; Schaefer B; Mittler J; Hoppe-Lotichius M; Quintini C; Aucejo F; Chapman W; Sapisochin G JAMA Surg; 2021 Jun; 156(6):559-567. PubMed ID: 33950167 [TBL] [Abstract][Full Text] [Related]
34. Significant Reduction in Posttransplant Hepatocellular Carcinoma Recurrence in the Post 6-Mo Waiting Policy Era. Mahmud N; Yagan L; Hoteit MA; Reddy KR; Abt PL; Abu-Gazala S Transplantation; 2024 May; 108(5):1172-1178. PubMed ID: 37953481 [TBL] [Abstract][Full Text] [Related]
35. Role of protein induced by vitamin-K absence-II in transplanted patients with HCC not producing alpha-fetoprotein. Lai Q; Ito T; Iesari S; Ikegami T; Nicolini D; Larghi Laureiro Z; Rossi M; Vivarelli M; Yoshizumi T; Hatano E; Lerut J Liver Transpl; 2024 May; 30(5):472-483. PubMed ID: 37729520 [TBL] [Abstract][Full Text] [Related]
36. Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II. Lv JY; Zhang NN; Du YW; Wu Y; Song TQ; Zhang YM; Qu Y; Liu YX; Gu J; Wang ZY; Qiu YB; Yang B; Tian DZ; Guo QJ; Zhang L; Sun JS; Xie Y; Wang ZL; Sun X; Jiang WT; Lu W Yonsei Med J; 2021 Jan; 62(1):29-40. PubMed ID: 33381932 [TBL] [Abstract][Full Text] [Related]
37. Relevance of Pre-Transplant α-fetoprotein Dynamics in Liver Transplantation for Hepatocellular Cancer. Grąt M; Krasnodębski M; Patkowski W; Wronka KM; Masior Ł; Stypułkowski J; Grąt K; Krawczyk M Ann Transplant; 2016 Feb; 21():115-24. PubMed ID: 26887339 [TBL] [Abstract][Full Text] [Related]
39. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686 [TBL] [Abstract][Full Text] [Related]
40. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation. Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]